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Hereditary hemochromatosis (HH) is one of the most common inherited conditions affecting individuals of Northern European 
descent. HH is inherited in an autosomal recessive pattern and is char-
acterized by increased iron absorption and tissue deposition (1). This 
may cause organ damage including cirrhosis, diabetes, cardiomyop-
athy, arthropathy and impotence. However, the majority of patients 
are asymptomatic at the time of diagnosis (1).
In 1996, Feder et al (2) identified the candidate gene for HH (sub-
sequently designated HFE), which encoded a major histocompatability 
complex class 1-like molecule that was involved in iron uptake. The 
two most common mutations are C282Y and H63D. The C282Y is a 
missense mutation, with a cysteine-to-tyrosine substitution at amino 
acid position 282. The C282Y mutation has been the most strongly 
implicated in the development of hemochromatosis. The H63D HFE 
mutation is a histidine-to-aspartic acid substitution at amino acid 
position 63. It has also been associated with hemochromatosis, but 
to a lesser extent than C282Y; the overall clinical significance of this 
mutation remains unclear. Some postulate that it plays a role in the 
development of the disease but that the penetrance tends to be low 
(3-8). Some studies have suggested that the H63D mutation is simply 
a polymorphism and may not be of clinical significance when present 
without any other mutations (9-11). 
If HH is recognized early in its course, phlebotomy therapy can 
prevent the complications of iron deposition. This has led to some 
discussion regarding screening individuals for HH because the condi-
tion meets many of the WHO criteria for population screening (1). 
However, the penetrance of the disease is variable and some studies 
have shown that even individuals homozygous for the C282Y muta-
tion may not develop clinically overt disease (12). 
In a previous study, we found that H63D homozygotes had a signifi-
cantly higher transferrin saturation than the wild-type genotype. We 
also showed that the degree of transferrin saturation elevation was 
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BACKGROUND: Previous research has suggested that the H63D 
HFE mutation is associated with elevated iron indexes. However, the 
true penetrance of this mutation remains unclear. 
OBJECTIVE: To assess the proportion of H63D homozygotes with 
laboratory abnormalities consistent with iron overload.
METHODS: The present study was a retrospective analysis of all indi-
viduals referred for HFE genotyping in Newfoundland and Labrador 
between 1999 and 2009, who were found to be homozygous for the 
H63D mutation. Using electronic health records, results of ferritin, 
transferrin saturation, aspartate aminotransferase and alanine amino-
transferase testing performed closest to the time of genetic testing were 
recorded for each patient. Iron overload was classified using previously 
published definitions from the HealthIron study. SPSS version 17.0 
(IBM Corporation, USA) was used for descriptive statistics and to 
compare means using one-way ANOVA.
RESULTS: Between 1999 and 2009, 170 individuals tested positive 
for H63D/H63D. At the time of genotyping, 28.8% had an elevated 
mean (± SD) ferritin level of 501±829 µg/L and 15.9% had an ele-
vated transferrin saturation of 0.45±0.18. At genotyping, 94 indi-
viduals had sufficient data available to classify iron overload status. 
Only three (3.2%) had documented iron overload while the majority 
(85.1%) had no evidence of iron overload. Sixty individuals had 
follow-up data available and, of these, only four (6.7%) had docu-
mented iron overload, while 45 (75.0%) had no evidence of iron 
overload. Only one individual had evidence of iron overload-related 
disease at genotyping and at follow-up.
CONCLUSIONS: H63D homozygosity was associated with an elevated 
mean ferritin level, but only 6.7% had documented iron overload at 
follow-up. The penetrance of the H63D mutation appeared to be low. 
Key Words: Ferritin; Hemochromatosis; HFE
La surcharge en fer est rare chez les patients 
homozygotes à la mutation H63D
HISTORIQUE : D’après des recherches passées, la mutation H63D 
HFE s’associe à des indices de fer élevés. Cependant, on n’en connaît pas 
la véritable pénétration.
OBJECTIF : Évaluer la proportion d’homozygotes H63D ayant des 
anomalies de laboratoire compatibles avec une surcharge en fer.
MÉTHODOLOGIE : La présente étude était une analyse rétrospective 
de toutes les personnes aiguillées pour le génotypage du HFE à Terre-
Neuve-et-Labrador entre 1999 et 2009, diagnostiquées comme homozy-
gotes à la mutation H63D. Au moyen des dossiers de santé électroniques, 
les chercheurs ont compilé pour chaque patient les résultats des tests de 
ferritine, de saturation de la transferrine, d’aspartate aminotransférase et 
d’alanine aminotransférase effectués le plus près du moment du test 
génétique. Ils ont classé la surcharge en fer d’après les définitions déjà 
publiées dans l’étude HealthIron et utilisé le logiciel SPSS version 17.0 
(IBM Corporation, États-Unis) pour compiler les statistiques descrip-
tives et comparer les moyennes à l’aide de l’analyse de variance unidirec-
tionnelle.
RÉSULTATS : Entre 1999 et 2009, 170 personnes ont obtenu des 
résultats positifs à la mutation H63D/H63D. Au moment du géno-
typage, 28,8 % présentaient un taux de ferritine moyen (± ÉT) élevé de 
501±829 µg/L et 15,9 %, une saturation de la transferrine élevée de 
0,45±0,18. Au génotypage, les chercheurs possédaient assez de données 
pour classer le statut de surcharge en fer de 94 personnes. Seulement trois 
(3,2 %) présentaient une surcharge en fer vérifiée, tandis que la majorité 
(85,1 %) n’en présentait aucune manifestation. Soixante personnes 
avaient des données de suivi, et de ce nombre, seulement quatre (6,7 %) 
avaient une surcharge en fer vérifiée, tandis que 45 (75,0 %) n’en présen-
taient aucune manifestation. Une seule personne avait des manifestations 
de maladie liée à une surcharge en fer à la fois au génotypage et au suivi.
CONCLUSIONS : L’homozygotie H63D s’associait à un taux de fer-
ritine moyen élevé, mais seulement 6,7 % présentaient une surcharge 
en fer vérifiée au suivi. La pénétration de la mutation H63D semblait 
faible. 
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comparable with C282Y homozygotes and compound heterozygotes. 
However, the clinical significance of these results could not be deter-
mined (13).
The purpose of the present study was to determine the penetrance 
of H63D homozygosity in a referred population in Newfoundland and 
Labrador by following a cohort of H63D homozygotes for evidence of 
iron overload. 
METHODS
The present study was approved by the Research Ethics Board of 
Memorial University of Newfoundland (St Johns, Newfoundland and 
Labrador) before commencement. Subjects were from Newfoundland 
and Labrador, an island comprised predominantly of Caucasians of 
Irish and English descent. The present study was a retrospective analy-
sis of all individuals referred for HFE genotyping in Newfoundland and 
Labrador from 1999 to 2009, who were identified to be homozygous for 
the HFE H63D mutation. The indication for genotyping was not 
stated on the requisition. There is only one laboratory in the province 
that performs genotyping for HH, enabling the authors to identify 
every individual who tested positive for H63D homozygosity. During 
the study period, only the C282Y and H63D mutations were assessed. 
Using electronic health records, age, sex, ferritin levels, serum iron, 
transferrin saturation, aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) levels closest to the time of genetic testing 
were recorded. To avoid including information from partially treated 
individuals, only bloodwork data obtained within six months of the 
genetic test were recorded. Measurement of transferrin saturation was 
not performed specifically in the fasting state. Follow-up laboratory 
values were recorded annually up to February 2011. Ferritin >335 µg/L, 
AST and ALT >37 IU/L and transferrin saturation >0.55 were con-
sidered to be abnormally elevated. Liver biopsy results and treatment 
with phlebotomy were also documented if recorded in the electronic 
health record. Iron overload was classified using previously published 
definitions from the HealthIron study (14) (Table 1). Briefly, this sys-
tem classifies patients into one of four iron overload categories, ran-
ging from no evidence of iron overload to iron overload-related 
disease.
The data were summarized using descriptive statistics. Incidence 
and prevalence of iron-overload were calculated using the number of 
patients with complete data as the denominator. SPSS version 17.0 
(IBM Corporation, USA) was used for descriptive statistics and to 
compare means using Student’s t test or one-way ANOVA; P≤0.05 was 
considered to be statistically significant.
RESULTS
A total of 4138 individuals underwent HFE genotyping in Newfoundland 
and Labrador between 1999 and January 2009. There were 366 (8.8%) 
C282Y homozygotes, 170 (4.1%) H63D homozygotes, 758 (18.3%) 
C282Y heterozygotes, 858 (20.7%) H63D heterozygotes, 267 (6.4%) 
compound heterozygotes and 1719 (41.5%) wild type. Of the 170 H63D 
homozygotes, 116 (68.2%) were male and 54 (31.8%) were female. The 
mean age at the time of genotyping was 48.9 years. At the time of 
genotyping, 28.8% had an elevated ferritin level and 15.9% had an 
elevated transferrin saturation. The mean ferritin level was 501 µg/L 
(range 16 µg/L to 7367 µg/L) (Figure 1) and the mean transferrin satura-
tion was 0.45 (range 0.10 to 0.98) (Figure 2). The mean AST level was 
56 IU/L, ALT 72 IU/L, bilirubin 22.6 µmol/L, international normalized 
ratio 1.5 and albumin 40.7 g/L (Table 2).
The mean follow-up duration was 4.2±2.6 years. There was no 
significant increase in the mean ferritin level over time. 
At the time of genotyping, the records of 94 individuals contained 
sufficient data to determine iron overload status (Figure 3). The 
Figure 1) Histogram of ferritin levels at the time of genotyping
Figure 2) Histogram of transferrin saturation levels at the time of 
genotyping
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ycneuqerF
Mean: 501 ug/L 
Range: 16-7367 ug/L
TABle 1
Iron overload categories*
Variable Clinical finding or laboratory measure
Documented iron overload At least one of the following:
1.  Increased iron content shown by hepatic iron staining 3 or 4, iron concentration >90 μmol/g or hepatic iron index >1.9, 
OR
2.  Serum ferritin >1000 μg/L at baseline with documented therapeutic venesection
Provisional iron overload 1.  Elevated serum ferritin (>300 μg/L for men and postmenopausal women, >200 μg/L for premenopausal women), AND
2.  Elevated transferrin saturation (>55% for men and >45% for women).
Either normal or elevated serum ferritin with normal transferrin saturation
Iron overload-related disease Meet the criteria for documented iron overload plus at least one of the following:
1.  Hepatocellular carcinoma
2.  Cirrhosis or fibrosis on liver biopsy
3.  Tenderness or effusion of the second and third metocarpophalangeal joints
4.  Elevated aspartate aminotransferase (>45 IU/L) or alanine aminotransferase (>40 IU/L)
5.  Diagnosis by a physician owing to symptoms associated with hereditary hemochromatosis
*Data adapted from the HeathIron study (14)
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majority of H63D homozygotes (85.1%) had no evidence of iron over-
load. Three (3.2%) had documented iron overload, with one (1.1%) 
meeting criteria for iron overload-related disease. Eleven (11.7%) had 
provisional iron overload. Sixty individuals had follow-up data avail-
able and, of these, four (6.7%) had documented iron overload. Only 
one (1.7%) of these individuals met criteria for iron overload-related 
disease. Eleven (18.3%) had provisional iron overload and 45 (75.0%) 
had no evidence of iron overload (Figure 4).
Only one individual had iron overload-related disease, both at the 
time of genotyping and at follow-up. Clinical records noted excess 
alcohol consumption in that case. Two (3.3%) individuals progressed 
from no evidence of iron overload to provisional iron overload. There 
were two individuals without sufficient data for a baseline classifica-
tion of iron status who did meet criteria for some degree of iron over-
load during follow-up. One met the criteria for documented iron 
overload and one met the criteria for provisional iron overload. 
Eight individuals underwent phlebotomy after genotyping. The 
details of the frequency and duration of phlebotomy were not avail-
able. None of the six individuals for whom follow-up data were avail-
able showed progression of iron overload. 
DISCUSSION
The results of the present study suggest a low penetrance of H63D 
homozyosity. Although serum ferritin levels were elevated at baseline, 
there was no significant increase in mean ferritin level for the cohort 
over time. Only three individuals met the criteria for iron overload at 
the time of genotyping and four at follow-up. Within this group, only 
one individual met the criteria for iron overload-related disease. That 
patient was documented to have abused alcohol, such that one cannot 
be certain whether iron overload was the primary cause of his liver 
disease. The majority of the individuals in our study showed no evi-
dence of iron overload (85.1% at baseline and 75.0% at follow-up). 
Only two individuals demonstrated any progression of their iron over-
load status during the study (3.3%).
In a previous study involving this same population, we found that 
H63D homozygosity was associated with a significantly higher mean 
transferrin saturation when compared with the wild-type genotype 
(0.44±0.18 versus 0.34±0.17; P<0.01). In that study, 42.0% of H63D 
homozygotes had elevated ALT levels compared with 30.1% of C282Y 
heterozygotes (P=0.04) (15).
The results of the present study are consistent with other studies 
that have found the H63D mutation to be associated with elevated 
iron levels (3,7,9,10,13,16,17). Phatak et al (17) found that the H63D 
homozygotes had a significantly elevated mean transferrin saturation 
when compared with the wild-type genotype, but this was not above 
the upper limit of normal. Gochee et al (10) found that 15% of male 
H63D homozygotes and 12% of male H63D heterozygotes had an ele-
vated transferrin saturation compared with only 5% in the wild-type 
genotype (P<0.01). Samarasena et al (13) conducted a study involving 
the Newfoundland and Labrador population and found that the 
H63D homozygotes had significantly elevated transferrin satura-
tion compared with the wild-type genotype (0.51±0.21 versus 
0.34±0.17; P<0.01). They also had an elevated mean ferritin level 
(920.3±1687.1 µg/L) but it was not statistically significant compared 
with the other genotypes (13). The  Hemochromatosis and Iron 
Overload Screening (HEIRS) study (18) also found elevated ferritin 
levels and transferrin saturation to be more common among com-
pound heterozygotes and H63D homozygotes when compared with the 
wild type, although the mean values were within the normal range.
Although the H63D homozygous mutation has been associated 
with elevated iron indexes, it is unclear whether these individuals 
require phlebotomy or whether they will progress to develop clinically 
significant iron overload. Several studies have suggested that H63D 
homozygosity has a much lower penetrance than C282Y homozygosity 
and are at a lower risk for developing clinically significant iron over-
load (4,11). Neghina et al (19) conducted a meta-analysis examining 
the association between the various HFE genotypes and iron overload. 
They found that in individuals with a clinical diagnosis of hemochro-
matosis, the C282Y homozygous genotype had a 100 times greater 
association with an elevated transferrin saturation (>55%) and ele-
vated serum iron and serum ferritin when compared with H63D homo-
zygotes. In cases for which hemochromatosis was documented by an 
elevated hepatic iron index and/or mobilizable iron by quantitative 
phlebotomy, C282Y homozygosity was 100 times more strongly associ-
ated with iron overload than H63D homozygosity (19).
Other studies have shown the H63D mutation to be associated 
with clinically significant iron overload. One study found that three of 
61 individuals with a phenotypic diagnosis of hemochromatosis were 
homozygous for the H63D mutation (5). These patients had either a 
hepatic iron index >1.9 or mobilizable iron stores of >4 g. A study by 
Brissot et al (20) determined the HFE genotypes of 217 patients with 
a phenotypic diagnosis of hemochromatosis. The majority (96.3%) 
were homozygous for the C282Y mutation. Four individuals were com-
pound heterozygotes, one was homozygous for the H63D mutation and 
one was heterozygous for the H63D mutation. Although the C282Y 
Figure 3) Iron overload status at time of genotyping
Figure 4) Iron overload status at follow-up
TABle 2
Baseline characteristics
Characteristic Mean (range)
Age at genotyping, years 48.9 (17–77)
Ferritin, μg/L 501 (16–7367)
Transferrin saturation 0.45 (0.10–0.98)
Aspartate aminotransferase, IU/L 56.3 (14–992)
Alanine aminotransferase, IU/L 71.7 (12–1190)
Bilirubin, μmol/L 22.6 (3–223)
International normalized ratio 1.5 (0.87–10.0)
Albumin, g/L 40.7 (21–48) 0
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mutation was most frequently associated with hemochromatosis, they 
did find that the H63D mutation occurred more frequently in the 
hemochromatosis population when compared with the control group. 
However, not all of these patients underwent liver biopsies and, in 
some, the phenotypic diagnosis was based solely on the elevated trans-
ferrin saturation.
Aguilar-Martinez et al (21) conducted a study involving a popula-
tion referred for HFE genotyping and found a wide variety of pheno-
types among the H63D homozygotes, ranging from normal to severe 
iron overload. Within this population, 24% of H63D homozygotes had 
a hemochromatosis phenotype characterized by an elevated ferritin 
and transferrin saturation level plus either iron overload on liver 
biopsy or quantitative phlebotomy. This study suggests a significantly 
higher penetrance of the H63D mutation than what was shown in our 
population. This difference is likely due to the reason for genotyping. 
Aguilar-Martinez et al (21) included patients referred for testing with 
either a personal or family history of iron overload, including 12 indi-
viduals (24% of the study population) previously diagnosed with 
hemochromatosis. Therefore, one would expect to find a more severe 
phenotype in this cohort. In our cohort, the reason for referral was not 
documented. Family history and elevated iron studies would have been 
the reason for referral in a proportion of our cohort. Some of the H63D 
homozygotes in our cohort had elevated transaminase levels, which 
likely was the reason for investigation in some patients. This hetero-
geneity in patients sent for genotyping is likely the reason why our 
cohort demonstrated a broader spectrum of iron overload severity than 
reported by Aguilar-Martinez et al (21).
Some have postulated that H63D homozygotes who develop clin-
ically significant iron overload may have another unidentified contrib-
uting mutation. One study examined H63D homozygotes with 
significantly elevated transferrin saturation and serum ferritin levels 
for mutations affecting other iron regulatory genes (22). The investi-
gators screened specifically for 18 known HFE, TFR2 and FPN1 muta-
tions and had complete sequencing of the HAMP gene. They were 
unsuccessful in finding any mutations affecting these genes in the 
45 H63D homozygotes. 
Some authors have proposed that environmental factors play a role 
in the variable penetrance of the hemochromatosis mutations. Aranda 
et al (16) found that iron intake, alcohol intake, tobacco habit and 
male sex were all positively associated with elevated iron studies in all 
HFE genotypes containing C282Y or H63D and in S65C homo-
zygotes. It has also been postulated that another process affecting the 
liver may actually be contributing to the increase in iron load. Bacon 
et al (11) measured the hepatic iron concentration of 132 patients 
with liver disease. Five of these were homozygous for H63D and there 
was no significant difference in the hepatic iron concentration or the 
hepatic index compared with the wild-type genotype. All five patients 
received a diagnosis of conditions other than hemochromatosis caus-
ing their liver disease (11).
The distribution of genotypes in our cohort does differ from a 
population-based study of hemochromatosis. The HEIRS study (18) 
examined a primary care population of 99,711 individuals. Within the 
Caucasian population of this group, 0.44% were homozygous for the 
C282Y mutation and 2.4% were homozygous for the H63D mutation 
(18). The individuals in our study were referred by a health profes-
sional for HFE genotyping and were, therefore, not a true population-
based sample. The distribution of C282Y (8.8%) and H63D 
homozygotes (4.1%) present in our population was closer to the 
referred population studied by Aguilar-Martinez et al (21), which con-
sisted of 18.4% C282Y homozygotes and 6.2% H63D homozygotes.
The present study had several strengths. It was a large cohort fol-
lowed for a long duration of time. Although the study was retrospect-
ive in nature, the data collection had been performed prospectively 
and provided us with ample data on a subset of patients. 
There were, however, some limitations to the present study. It was 
retrospective in design and, therefore, was limited to the data that 
could be obtained from the electronic health records. Although we 
had the genotyping results from all individuals in the province, access 
to the primary health record (including clinical letters, additional 
laboratory tests, imaging and pathology results) was limited to only a 
subset of patients in the Eastern Health region. Consequently, only 
partial (or no) baseline and follow-up data were available for 69.4% of 
patients. We do not believe that the reason for incomplete data for 
some patients would bias the findings to affect the validity of our 
results. We were unable to obtain clinical information, such as alcohol 
consumption, for most individuals. However, for 30% of patients, we 
did have sufficient baseline and follow-up data to assess the natural 
history of H63D homozygosity. The duration of follow-up was limited 
by the health records themselves and when genotyping became avail-
able in this region. It is possible that if patients were followed for a 
longer duration, the results would be different.
The indication for genotyping was unknown for all patients in the 
cohort. Although we did find that the H63D homozygous mutation 
was associated with significantly elevated ferritin levels, it is possible 
that this was the reason the individuals underwent genotyping, which 
would bias these results.
CONCLUSION 
The H63D homozygous mutation was associated with elevated iron 
indexes. Despite this, the incidence of documented iron overload 
was low (6.7% at follow-up) and only one individual met the cri-
teria for iron overload-related disease. The results of our study 
indicate that although the H63D mutation may be related to altera-
tions in iron indexes and transaminase levels, the penetrance of this 
mutation in causing iron overload-related disease is low. 
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